Share this:
Check out a few of the most popular News Network stories on @mayoclinic social media this past week.
Mayo Clinic recognized as 'World's Best Hospital' by Newsweek for the seventh straight year
Mayo Clinic has again received the No. 1 ranking in Newsweek's list of the "World's Best Hospitals." This is the seventh straight year Mayo Clinic has received the top ranking.
"This continued recognition is a tribute to our dedicated staff who consistently deliver unparalleled, compassionate care to our patients," says Gianrico Farrugia, M.D., president and CEO of Mayo Clinic.
Mayo Clinic Minute: Sleep and heart health
Does how much you sleep affect your heart? According to health officials, adults who sleep fewer than seven hours each night are more likely to experience health problems.
Dr. Juan Cardenas Rosales, an internal medicine physician at Mayo Clinic, stresses that adequate sleep is crucial for your overall well-being, including your heart health.
Mayo Clinic Minute: Know the warning signs of hypertrophic cardiomyopathy
It's often silent but can be a deadly killer. Hypertrophic cardiomyopathy is a genetic condition that occurs in 1 in 500 people.
Dr. Said Alsidawi, a Mayo Clinic cardiologist, says the problem is that many people don't even know they have it because they have no symptoms. And in many cases, the first presentation is sudden cardiac death.
Researchers find caregiving worsens menopause symptoms
In a first-of-its-kind study, Mayo Clinic researchers found that women 45–60 years old who are managing family caregiving and menopause face nearly double the risk of moderate to severe menopause symptoms. Women in the sandwich generation are especially affected. The sandwich generation is a term used for people who often juggle caring for both children and aging adults, balancing responsibilities like feeding, cleaning and medical care.
New drug may reduce need for aortic valve surgeries by slowing disease progression
Researchers at Mayo Clinic are exploring the use of a new drug called ataciguat to manage aortic valve stenosis. Results from preclinical and clinical studies, published in Circulation, show that ataciguat has the potential to significantly slow disease progression. The final step to establish the drug's long-term effectiveness and safety is a phase 3 trial, and efforts to launch that pivotal trial are soon to be underway with an industry partner.
